|
Julian Hanak BSc, MSc
Chief Executive Officer
Purespring Therapeutics Ltd
UK
|
Julian has worked in the biotechnology and biopharmaceutical sector for more than 25 years, holding senior leadership positions in small biotech, CDMO and large pharma companies. Graduating as a Biochemist from University College London he completed his Master’s at Bangor University before working in research at the Nation Institute for Medical Research (MRC), Bioproducts Laboratories and Astra Zeneca. He gained extensive Gene Therapy drug development, manufacturing and business development experience at Cobra Biologics, NightStar Therapeutics, Biogen and most recently Purespring Therapeutics. He is currently the CEO at Purespring, the first company to specialise in targeted gene therapy treatments for kidney diseases.